anti-IL-13 neutralizing antibody

Anti-IL-13 neutralizing antibodies are a class of monoclonal antibodies designed to bind specifically to interleukin-13 (IL-13), a key type 2 (Th2) cytokine. IL-13 is a central mediator in allergic inflammation, airway hyperresponsiveness, and tissue remodeling, and it plays a significant role in the pathogenesis of conditions such as atopic dermatitis, asthma, and fibrosis. By neutralizing IL-13, these antibodies prevent its interaction with the IL-4Rα/IL-13Rα1 receptor complex, thereby inhibiting downstream signaling through the STAT6 pathway. This class includes approved therapies like tralokinumab and lebrikizumab, and it is being actively researched for its potential to mitigate chronic inflammation and intestinal fibrosis in conditions like Crohn's disease.

Other names

anti-IL-13 antibodyanti-IL13 antibodyanti-IL 13 antibodyIL-13 neutralizing antibodyIL13 neutralizing antibodyIL 13 neutralizing antibodyIL-13 antagonist antibodyIL13 antagonist antibodyIL 13 antagonist antibody